US FDA places clinical hold on Intellia’s gene therapy trials; shares fall
The hold follows a serious safety event involving liver-related complications in a participant receiving the investigational…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Armata AP-SA02 shows promise for SAB in Phase IIa trial, underscoring growing potential of phage…
Phase IIa data show faster infection resolution and shorter hospital stays when AP-SA02 is added to standard antibiotic therapy,…
Alembic Pharmaceuticals receives USFDA approval for Ticagrelor Tablets, 60 mg
Approval aligns Ticagrelor 60 mg with its reference drug Brilinta; estimated market size at US$ 236 million
CEPI, University of Oxford and Serum Institute to establish investigational Nipah virus vaccine…
Up to 100,000 ChAdOx1 NipahB doses to support Phase II trial and potential emergency outbreak response
Merck & Co., Inc. and Eisai announce Phase 3 trial results for WELIREG plus LENVIMA in advanced…
LITESPARK-011 trial meets primary endpoint of progression-free survival in patients previously treated with anti-PD-1/L1 therapy
Akums Drugs & Pharmaceuticals begins construction of first overseas manufacturing facility in…
The Zambia-based facility will cover 40 acres, produce multiple dosage forms, and create more than 1,000 jobs as part of Akums’…
Thermo Fisher Scientific inaugurates expanded R&D Centre of Excellence in Bengaluru
The company invests over INR 160 crores to expand its Bengaluru facility, supporting antibody research, innovation, and local…
U.S. FDA approves Eli Lilly’s single-injection, once-monthly Omvoh regimen for adults with…
The approval allows a simplified once-monthly 200 mg maintenance dose of Omvoh (mirikizumab-mrkz) for adults with moderately to…
Sanofi India appoints Deepak Arora as Managing Director effective October 27, 2025
The appointment, approved by Sanofi India’s Board, will see Arora lead the company’s strategic priorities and operational…
MEDINET Japan and Stempeutics India sign option licence agreement for Stempeucel in Japan
The agreement grants MEDINET rights to develop and commercialise Stempeucel for CLTI indication in Japan, with manufacturing to…